Traduction de «Endocrine-disrupting end point » (Anglais → Français) :

endocrine-disrupting end point [ endocrine endpoint ]

11. Calls on the Commission to introduce in all relevant EU legislation appropriate testing requirements for the identification of substances with endocrine-disrupting properties; considers that the most recently validated and internationally recognised testing methods – such as those developed by the OECD, the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) or the US Environmental protection Agency (EPA) Endocrine Disruptor Screening Program – must be implemented; notes that the OECD programme of testing methods covers sex hormones and thyroid hormones as well as steroidogenesis; points out, on ...[+++]the other hand, that there are no tests for many other areas of the endocrine system, e.g. insulin and growth hormones; considers that testing methods and guidance documents should be developed so as to take better account of endocrine disrupters, possible low-dose effects, combination effects and non-monotonic dose-response relationships, in particular with regard to critical windows of exposure during development;

12. Calls on the Commission to introduce in all relevant EU legislation appropriate testing requirements for the identification of substances with endocrine-disrupting properties; considers that the most recently validated and internationally recognised testing methods – such as those developed by the OECD, the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) or the US Environmental protection Agency (EPA) Endocrine Disruptor Screening Program – must be implemented; notes that the OECD programme of testing methods covers sex hormones and thyroid hormones as well as steroidogenesis; points out, on ...[+++]the other hand, that there are no tests for many other areas of the endocrine system, e.g. insulin and growth hormones; considers that testing methods and guidance documents should be developed so as to take better account of endocrine disrupters, possible low-dose effects, combination effects and non-monotonic dose-response relationships, in particular with regard to critical windows of exposure during development;

16. Considers that it should be possible for decision-making bodies to deal with substances having the same modes of action and properties on a group basis when sufficient data is available, while in the absence of sufficient data it may be useful to group substances on the basis of structural similarity, for example in order to establish priorities for further testing, in order to protect the public as quickly and effectively as possible from the effects of exposure to endocrine disrupters, and limiting the number of animal tests; takes the view that grouping chemicals with structural similarity should be applied if the manufacturer or importer is unable to demonstrate the safety of a chemical to the satisfaction of the relevant decision making ...[+++] bodies; points out that, in such cases, these bodies may use information from chemicals of similar structure to complement the available data on a given chemical that is being considered by the bodies in order to reach conclusions regarding which subsequent steps need to be taken;

The Member States concerned shall ensure that the applicant submits to the Commission the information set out in points (1) and (2) by 30 November 2011, the information set out in points (3) by 31 May 2013, the information set out in point (4) within two years after the adoption of the OECD test guidelines on endocrine disruption and the information set out in point (5) within two years after the adoption of specific guidance’.